Skip to main content
Premium Trial:

Request an Annual Quote

Accelrys Sees Net Income, Revenues Slide in Fiscal Q2

NEW YORK (GenomeWeb News) – Accelrys today posted a 7-percent decline in revenues for its second fiscal quarter, alongside a 19-percent decrease in net income.
Revenue for the quarter ended Sept. 30 declined to $20.2 million from $21.7 million in the second quarter of 2005. The company attributed the slide to “an expected decrease in revenues from certain products that were de-emphasized in connection with the company's restructuring and product line adjustments that have occurred over the past two years.”
Second-quarter net income fell to $900,000 from $1.2 million in the prior-year period. Excluding stock-based compensation expense, non-GAAP net income increased by 65 percent to $2.3 million from $1.4 million in the second quarter of 2005.
Product development costs declined 12 percent to $4.9 million from $5.6 million in the quarter ended Sept. 30, 2005.
At Sept. 30, Accelrys had total cash, cash equivalents, restricted cash, and marketable securities of $61.2 million.

Filed under

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.